☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Multiple Cancer
Apobiologix's Bambevi (biosimilar- bevacizumab) Receives Health Canada Approval for Multiple Cancer Indications
September 27, 2021
CStone Signs a License Agreement with LegoChem for LCB71 to Treat Multiple Cancer Indications
October 29, 2020
Centus Biotherapeutics' Equidacent (bevacizumab- biosimilar) Receives CHMP's Positive Opinion for the Treatment of Multiple Cancer...
July 27, 2020
Thermo Fisher Scientific Collaborates with Janssen to Co-Develop CDx for Multiple Cancer Indications
March 12, 2020
Mount Sinai Signs a Multi-Year Collaboration with Harbour BioMed to Develop Novel Biotherapies for Multiple Cancer Indications and...
March 6, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.